Category: biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma crease, occupying the top science place at Sanofi.Quigley will

.Sanofi has created an overdue entry to the radioligand party, spending 100 thousand euros ($ 110 million) upfront for international liberties to a neuroendocrine cyst

.Sanofi has stopped a phase 2 ordeal of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 prevention hardship from its own

.Sangamo Rehabs has actually recognized a quick way to market for its Fabry illness prospect, lining up along with the FDA on a path that

.Sage Rehabs’ most recent effort to diminish its pipe and labor force will view a third of the biotech’s workers heading for the exits in

.Matt Gline is back with a brand new ‘vant’ provider, after the Roivant Sciences chief executive officer paid Bayer $14 thousand in advance for the

.Roche has come back the civil liberties to UCB’s anti-tau antitoxin bepranemab, ignoring a $120 million bank on the Alzheimer’s illness drug prospect on the

.Roche is actually storing out chances that its own injectable excessive weight prospect might at some point show 25% weight reduction in late-stage tests, the

.Roche’s constant cough plan has actually sputtered to a standstill. The drugmaker, which axed the program after the medicine prospect let down in stage 2,

.After creating a genetics therapy relationship along with Dyno Rehabs in 2020, Roche is back for even more.In a new deal potentially worth more than